Some patients who use Genzyme's treatments are worried that their close relationship with the biotech firm will end if it is acquired by a bigger company. Meanwhile, Genzyme's strategy of reaching out and regularly checking on patients has prompted other drug companies to try the same to expand their share of the market for rare illnesses, such as Pompe and Gaucher diseases.

Related Summaries